# A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

> **NCT05283694** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** risankizumab
- **DRUG:** risankizumab

## Key facts

- **NCT ID:** NCT05283694
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-11
- **Primary completion:** 2018-06-12
- **Final completion:** 2018-06-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05283694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05283694, "A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05283694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*